Exclusive By Lev Facher Biden’s high-stakes biomedical science agency ARPA-H will be part of the NIH — but there’s a twist
Exclusive By Lev Facher Lawmakers and a Pelosi aide turn lobbyist to push for new health agency’s independence
Exclusive By Megan Molteni New details emerge about a U.S. scientist’s obscured role in the ‘CRISPR babies’ scandal
Exclusive By Rachel Cohrs The Catholic hospital system Ascension is running a Wall Street-style private equity fund
Exclusive By Adam Feuerstein, Matthew Herper and Damian Garde Inside ‘Project Onyx’: How Biogen used an FDA back channel to win approval of its polarizing Alzheimer’s drug
Exclusive By Rachel Cohrs The Trump administration quietly spent billions in hospital funds on Operation Warp Speed
Exclusive By Rachel Cohrs White House’s Jen Psaki offered a binder full of Covid spending details. Taking a peek was a process
Exclusive By Ed Silverman Justice Department probes Bausch Health over marketing for dermatology drugs
Exclusive By Nicholas Florko Warren, Grassley threaten to slap FDA with a 30-day deadline for OTC hearing aid rules
Exclusive By Matthew Herper Douglas Melton, noted stem cell researcher, leaves Harvard for Vertex to create diabetes treatments
Exclusive By Nicholas Florko and Rachel Cohrs More Democrats flag ‘questions,’ remain uncertain about Biden’s FDA pick, Robert Califf
Exclusive By Casey Ross He founded what became IBM’s most valuable health database. Now, he’s sounding an alarm about patient privacy
Exclusive By Rachel Cohrs The Biden administration used billions in hospital Covid-19 funds to pay drugmakers
Exclusive By Damian Garde and Adam Feuerstein With its Alzheimer’s drug in turmoil, Biogen eyes a list of potential acquisitions
Exclusive By Eric Boodman A tiny Florida company got more of a scarce Covid therapy than some big hospitals, raising equity questions
Exclusive By Adam Feuerstein and Damian Garde Moderna, Amgen among biotech heavyweights pulling out of JPM conference over Covid concerns
Exclusive By Katie Palmer ‘A multi-decade journey’: Chan Zuckerberg Initiative invests another $3.4 billion to advance scientific tools
Exclusive By Kate Sheridan Flagship to launch a new startup focused on neurodegenerative conditions, including Parkinson’s
Exclusive By Rachel Cohrs How Nancy Pelosi almost killed drug pricing reform — a gamble that expanded Democrats’ final deal
Exclusive By Rachel Cohrs and Nicholas Florko Key Senate committee considers a carveout for small biotech companies in drug pricing reforms
Exclusive By Adam Feuerstein and Damian Garde Biogen’s Aduhelm sales slower than disclosed, forcing company to consider cost-cutting measures
Exclusive By Nicholas Florko and Rachel Cohrs Senate considers pegging Medicare drug prices to deeply discounted Veterans Affairs rates
Exclusive By Erin Brodwin Cityblock Health raises another mega-round of funding, tipping its valuation over $5 billion
Exclusive By Nicholas Florko ‘Change is messy’: Inside the tumultuous efforts to stabilize BIO, the biotech lobby
Exclusive By Olivia Goldhill Inside Pfizer’s labs, ‘variant hunters’ race to stay ahead of the pandemic’s next twist
Exclusive By Kate Sheridan Flagship, Orbimed, ARCH, Alta top list of high-performing biotech venture capital firms
Exclusive By Damian Garde Sesen Bio trial of cancer drug marked by misconduct and worrisome side effects, documents show
Exclusive By Megan Molteni Anti-aging foundation’s CEO left amid an investigation of co-founder Aubrey de Grey